Pneumococcal conjugate vaccine is efficacious against invasive disease with fewer doses than currently recommended.
Nohynek
H
H
National Public Health Institute, Helsinki, Finland. hanna.nohynek@ktl.fi
D015982:Bias; D016022:Case-Control Studies; D002675:Child, Preschool; D003906:Developing Countries; D005060:Europe; D005069:Evaluation Studies as Topic; D019317:Evidence-Based Medicine; D006040:Goals; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D022401:Meningococcal Vaccines / Q000008:administration & dosage*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D014481:United States; D014611:Vaccination / Q000592:standards*; D018074:Vaccines, Conjugate / Q000008:administration & dosage; D014944:World Health Organization
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate